aMoon Growth Fund Limited Partnership - 18 Oct 2023 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.

Role: 10%+ Owner
Signature: /s/ Yair Schindel, on behalf of himself and the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership
Issuer symbol: N/A
Transactions as of: 18 Oct 2023
Net transactions value: $0
Form type: 4
Filing time: 23 Oct 2023, 06:43:18 UTC
Previous filing: 30 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADXS	Common Stock	Other	$0	0	0%	$0.000000^*	560,602	18 Oct 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

aMoon Growth Fund Limited Partnership is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 is filed to report that the beneficial interest of the Reporting Person in Ayala Pharmaceuticals, Inc., (the "Registrant") was reduced below 10% due to dilution resulting from issuance of approximately 5,913,480 shares of the Common Stock of the Registrant on October 18, 2023 to the former holders of Biosight Ltd. ("Biosight") upon the consummation on October 18, 2023 of the transaction contemplated by the Agreement and Plan of Merger and Reorganization, dated July 26, 2023, by and among the Registrant, Advaxis Israel Ltd. and Biosight. The transaction is more fully described in the Registrant's Form 8-K filed with the Securities and Exchange Commission on October 20, 2023.
F2	The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.

Content

This Form 4 is filed to report that the beneficial interest of the Reporting Person in Ayala Pharmaceuticals, Inc., (the "Registrant") was reduced below 10% due to dilution resulting from issuance of approximately 5,913,480 shares of the Common Stock of the Registrant on October 18, 2023 to the former holders of Biosight Ltd. ("Biosight") upon the consummation on October 18, 2023 of the transaction contemplated by the Agreement and Plan of Merger and Reorganization, dated July 26, 2023, by and among the Registrant, Advaxis Israel Ltd. and Biosight. The transaction is more fully described in the Registrant's Form 8-K filed with the Securities and Exchange Commission on October 20, 2023.

The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.